Professor University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
This session will provide an update from the AMP Pharmacogenetics (PGx) Working Group of the AMP Clinical Practice Committee. The goals of this international collaborative working group are to assess current evidence and develop recommendations for clinical testing of pharmacogenomic alleles. The working group began in 2018 and has published recommendations for clinical genotyping of CYP2C19, CYP2C9, warfarin response genes, CYP2D6, TPMT/NUDT15, and CYP3A4/5, with recommendations for DPYD under way. This interactive session provides attendees an opportunity to provide feedback to the Working Group as we prepare for an update and evaluation of the previous manuscripts, along with identification of existing practice gaps that remain to be addressed.
Learning Objectives:
Describe the importance of allele selection for pharmacogenomic (PGx) test design
